Acadian Asset Management’s LENZ Therapeutics LENZ Stock Holding History

Acadian Asset Management’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$188K	Buy	+20,611	New	+$290K	﹤0.01%	1608
2023 Q3	–	Sell	-32	Closed	–	–	1885
2023 Q2	$0	Hold	32	–	–	﹤0.01%	1941
2023 Q1	$0	Sell	32 -3,654	-99%	-$59.1K	﹤0.01%	2002
2022 Q4	$85K	Buy	+3,686	New	+$85.4K	﹤0.01%	1474
2022 Q3	–	Sell	-12,440	Closed	-$239K	–	1881
2022 Q2	$239K	Buy	+12,440	New	+$277K	﹤0.01%	1156

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Acadian Asset Management's LENZ Position: Q1 2026 in Review

Acadian Asset Management opened a new position in LENZ Therapeutics (LENZ) in Q1 2026: 20,611 shares worth $188K. The stake represents ﹤0.01% of the portfolio and ranks #1608 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in LENZ as recently as Q2 2023.

Acadian Asset Management first reported a position in LENZ in Q2 2022 and has held it in 5 quarters since. The position peaked at $239K in Q2 2022. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

Acadian Asset Management held 20,611 shares of LENZ Therapeutics worth $188K as of Q1 2026.
LENZ Therapeutics was a new Acadian Asset Management position in Q1 2026.
LENZ Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1608 holding.
Acadian Asset Management first reported a position in LENZ Therapeutics in Q2 2022 and has held it in 5 quarters since.
Acadian Asset Management's LENZ Therapeutics position peaked at $239K in Q2 2022.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.